Prof. Dr. Erik C. Böttger is Professor of Clinical Microbiology, Director and Chairman of the Institute of Medical Microbiology at the University of Zurich. He is a world renowned expert in the areas of antibacterial drug resistance, drug susceptibility testing and antibiotic drug discovery. Erik has authored more than 250 peer-reviewed articles including some of the most influential and seminal papers in the field of antibacterial drug resistance. He has received numerous awards for his work, such as the prestigious Körber Award for European Science. He is ranked among the world’s most cited and influential microbiologists of the past two decades.
Prof. Dr. David Crich is Schaap Professor of Chemistry at Wayne State University in Detroit, MI, USA. He graduated Docteurès Sciences in organic chemistry from the Université de Paris Sud. After postdoctoral studies at the CNRS Institute de Chimie des Substances Naturelles (ICSN), David joined the faculty of University College London, UK, before moving to the University of Illinois at Chicago and eventually WSU. He has also served as the Directeur (Head) of the ICSN. He has over thirty years of experience in organic and medicinal chemistry research, with particular emphasis on carbohydrate chemistry and currently serves as a permanent member of the US National Institute of Health Synthetic and Biological Chemistry A Study Section. David has published around 350 peer-reviewed articles in the field of organic chemistry and has received numerous awards for his work including most recently the 2017 CS Hudson Award in Carbohydrate Chemistry from the American Chemical Society.
Prof. Dr. Dr. Gunter Festel is an experienced entrepreneur with a deep understanding of scientific and business aspects stemming from his over 20 years' of experience in the development and commercialization of technology and innovation. He has previously worked for Bayer, McKinsey, Arthur D. Little and has since founded his own company, Festel Capital. Over the last 10 years, he has co-founded fifteen technology companies and successfully managed two exits by means of acquisition by industrial partners. Furthermore, he is a professor for Life Science Entrepreneurship at the Technische Universität (TU) Berlin and Berlin Institute of Technology; research fellow at the University of Basel within the Chair of Financial Management and long-standing guest lecturer at the University of St. Gallen at the Institute of Technology Management and the Institute of Information Management.
Dr. Sven Hobbie has been a principal scientist in the development of Juvabis’ proprietary technology platform. Sven holds a PhD of the ETH Zurich and has more than 15 years of hands-on research experience in microbiology and anti-invective drug discovery, with positions held at the Michigan State University, Universität Konstanz, Universität Zürich, the Massachusetts Institute of Technology, and Visterra Inc. Sven’s track record in applied and translational sciences includes both biologics and small molecule therapeutics and is reflected in various research publications, invention disclosures, patents, an MIT Innovation Grant, a PhD award, and an invitation to join the Duke-NUS Medical School as Adjunct Assistant Professor. Sven has contributed to establishing an MIT research institute in Singapore and successfully spinning out the antiviral drug discovery company Visterra Singapore.
Prof. Dr. Andrea Vasella is a Professor emeritus of Chemistry at the ETH Zürich still highly active at the ETH with full access to facilities. Andrea obtained his Ph.D. from the ETH with distinction. After postdoctoral studies at King’s College, London, and Harvard University, he returned to Switzerland for faculty positions at the University of Fribourg, the University of Zürich, and the ETH Zürich. Andrea has over forty years of experience in organic and medicinal chemistry, and over thirty years as consultant of CROs, pharma and agro companies. His track record comprises some 340 peer-reviewed articles and several distinguished awards for his work.